Advanced Accelerator Applications

3 trials Commercial sponsor Merged from 2 name variants

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

7 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (FiH)

Phase III: 1 Phase II: 1 Phase I (FiH): 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gastroenteropancreatic neuroendocrine tumour disease 2 Neuroendocrine tumour 2

Top IMPs

L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE 2 LUTETIUM (177LU) OXODOTREOTIDE 2 LUTETIUM (177LU)-NEOBOMB1 1 NEOB 1 OCTREOTIDE 1

All trials

3 total

Study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs and PPGLs. Ended

2023-507444-37-00 Phase II 3 countries L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended

2023-507443-10-00 Phase III 5 countries L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE…
NeoRay - Phase I/IIa trial of [177Lu]-NeoB in patients with advanced solid tumors and with [68Ga]-NeoB lesion uptake. Ended

2023-507170-41-00 Phase I (FiH) 4 countries LUTETIUM (177LU)-NEOBOMB1; NEOB

Showing 1–3 of 3 trials

← All sponsors A–Z